PS0026
PS0026
A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice
Brief summary
The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.
Medical Condition
Plaque Psoriasis
Min. Age
18
Years
Max. Age
-
Who Can Join?
All
Status
Active, not recruiting
Inclusion criteria
- The patient is ≥18 years of age at observational point 1 - The patient must have a clinical diagnosis of moderate to severe Plaque psoriasis according to the diagnostic criteria used by the physician in routine clinical practice - The patient has an available PASI assessment prior to the first certolizumab pegol dose according to the standard of care - The patient must be newly prescribed with certolizumab pegol - If a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study
Exclusion criteria
Not applicable
Study Medication Description
Study Medication:
Cimzia®
Other Descriptive Name:
certolizumab pegol
Placebo
No
Comparator:
No
Refer to a friend
Study Dates
August 2019
Actual Start Date of Enrollment
December 2022
Planned Study Completion Date